Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Can they bring Otenaproxesul to market?

<< Previous

Bullboard Posts

Next >>

Comment by Bookworm28on Jun 24, 2021 11:51pm

156 Views

Post# 33449093

RE:RE:Can they bring Otenaproxesul to market?

Thanks for the info Pragmatist.

The net can be a real pain at times when doing DD. Found one link that looked pretty legit, but they said Naproxen was under patent until March 2026. Another that said it wasn't under patent. Given the age of Naproxen, your comments, Nuance's investment, I'm thinkin' ATE is fine when it comes to IP considerations. I'd like to have received an email from the Co. to confirm. Not very impressed. with their IR.

Thanks again for your reply. H2 should breath some life into the stock. GLTA.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"